Patents Assigned to Zhejiang Hisun Pharmaceutical Co., Ltd.
-
Patent number: 11897863Abstract: Indazole derivatives represented by formula (I) or stereoisomers, tautomers, and pharmaceutically acceptable salts thereof are provided. A preparation method of indazole derivatives represented by formula (I) and a method of use of the indazole derivatives as therapeutic agents is also provided.Type: GrantFiled: August 15, 2019Date of Patent: February 13, 2024Assignee: ZHEJIANG HISUN PHARMACEUTICAL CO., LTD.Inventors: Yongping Lu, Cheng Ye, Wenjian Qian, Taishan Hu, Lei Chen
-
Publication number: 20240018130Abstract: The present invention relates to a pyrimidine derivative, a method for preparing same and use thereof in medicine. In particular, the present invention relates to a pyrimidine derivative represented by general formula (I), a method for preparing same and a pharmaceutically acceptable salt thereof as well as use thereof as a therapeutic agent, in particular as a FGFR4 kinase inhibitor, definitions of each substituent in the general formula (I) being the same as those defined in the description.Type: ApplicationFiled: September 14, 2023Publication date: January 18, 2024Applicant: Zhejiang Hisun Pharmaceutical Co., Ltd.Inventors: Lei Chen, Dongliang Guan, Hua Bai, Jun Gou, Weifeng Zhao, Zhongli Wang, Long Ling, Yutao Ma
-
Publication number: 20230373972Abstract: The present disclosure relates to a piperazine derivative, a preparation method therefor, and use thereof in medicine. Specifically, the present invention relates to a piperazine derivative represented by general formula (I), a preparation method therefor, and a pharmaceutically acceptable salt or prodrug thereof, and use thereof as a therapeutic agent, in particular, as an inhibitor of coagulation factor XIa (FXIa), wherein the definition of each substituent in general formula (I) is the same as that in the description.Type: ApplicationFiled: September 16, 2021Publication date: November 23, 2023Applicants: Zhejiang Hisun Pharmaceutical Co., Ltd., Shanghai Aryl Pharmtec Co., Ltd.Inventors: Haibo QIU, Yutao MA, Ahuan CHEN, Yabo ZHU, Binhao ZHANG, Yongping LU, Cheng YE, Taishan HU, Wenjian QIAN, Lei CHEN
-
Publication number: 20230348467Abstract: The present invention relates to heteroaryl derivatives, preparation methods therefor, and applications thereof in medicine. Specifically, the present invention relates to a heteroaryl derivative represented by general formula (AI), a preparation method therefor, and a pharmaceutically acceptable salt, and use thereof as a therapeutic agent, in particular, as an SHP2 allosteric inhibitor, wherein the definition of substituents in general formula (AI) is the same as that in the description.Type: ApplicationFiled: January 12, 2021Publication date: November 2, 2023Applicants: Zhejiang Hisun Pharmaceutical Co., Ltd., Hisun AccuRay Therapeutics Co., Ltd.Inventors: Xiangui Huang, Yanghui Guo, Zongxing Qiu, Pingyan Bie, Weiwei Liao, Qingyan Yan, Weichao Shen, Hai Cao, Qingna Xing, Xin Wang, Qi Cao, Lichen Meng, Nuoyi Wu, Wenpeng Li, Cheng Ye, Taishan Hu, Lei Chen
-
Publication number: 20230295163Abstract: The present invention relates to a tetracyclic derivative, a method for preparing same and the use thereof in medicine. In particular, the present invention relates to a tetracyclic derivative represented by general formula (I), a method for preparing same and a pharmaceutically acceptable salt thereof, and the use thereof as a therapeutic agent, especially as a K-Ras GTPase inhibitor, with definitions of each substituent in general formula (I) being the same as of which are defined in the description.Type: ApplicationFiled: August 19, 2021Publication date: September 21, 2023Applicants: ZHEJIANG HISUN PHARMACEUTICAL CO., LTD., SHANGHAI ARYL PHARMTECH CO., LTD.Inventors: Youxi CHEN, Chaoying CHENG, Liang GONG, Wentao MAO, Qing XIANG, Weifeng ZHAO, Wenwen ZHAO, Yanling HE, Mingjiang ZHU, Cheng YE, Taishan HU, Wenjian QIAN, Lei CHEN
-
Publication number: 20230242522Abstract: The present invention relates to a pharmaceutically acceptable salt of (S)-2-(6-fluorobenzo[d]oxazol-2-yl)-6-methoxy-5-((5-methoxypyridin-2-yl))methoxy)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid, a preparation method therefor, a pharmaceutical composition comprising the pharmaceutically acceptable salt thereof, and the use thereof as a therapeutic agent, in particular as an angiotensin II type-2 receptor antagonist.Type: ApplicationFiled: June 25, 2021Publication date: August 3, 2023Applicants: ZHEJIANG HISUN PHARMACEUTICAL CO., LTD., SHANGHAI ARYL PHARMTECH CO., LTD.Inventors: Yanghui GUO, Lichen MENG, Xiangui HUANG, Weiwei LIAO, Yongxiang GONG, Daiwang XU, Taishan HU, Lei CHEN
-
Patent number: 11622939Abstract: An HS-25 tablet, an HS-25 solid dispersion composition, a preparation method therefor and usage thereof. The HS-25 tablet is made by using HS-25 and excipients for wet granulation, drying, granulating and tablet pressing.Type: GrantFiled: November 23, 2018Date of Patent: April 11, 2023Assignee: ZHEJIANG HISUN PHARMACEUTICAL CO., LTD.Inventors: Li Ding, Jun Dai, Chunrong Feng, Changliang Dai
-
Patent number: 11421255Abstract: A method for enzymatic preparation of fludarabine phosphate, comprising reaction of fludarabine with a high-energy phosphate compound under the action of deoxyribonucleic acid kinase. According to said method, acetate kinase and acetyl phosphate free acid or acetyl phosphate are also added. The technical problems present in the existing processes are successfully addressed by employing the enzymatic process to prepare the fludarabine phosphate. The usage of the high-energy phosphate compound is reduced by means of adding acetate kinase to recycle and regenerate a small amount of the high-energy phosphate compound, thereby reducing the generation of by-products having similar structures to the fludarabine phosphate, enhancing the operation convenience of purification steps in the industrial production of the fludarabine phosphate. The process is environment friendly, the reaction conditions are moderate, the cost is low, and the yield and the purity of the product obtained are high.Type: GrantFiled: January 20, 2016Date of Patent: August 23, 2022Assignee: Zhejiang Hisun Pharmaceutical Co., Ltd.Inventors: Dejin Fu, Yong Yang, Wei Yan, Weijiang Wen, Xiande Gu, Hua Chen, Xiaojun Ma, Ling Zhang, Kaijun Wang
-
Publication number: 20220257602Abstract: The present invention relates to an alkyne derivative, a preparation method for same, and applications thereof in medicine. Specifically, the present invention relates to the alkyne derivative as represented by formula (I), the preparation method for same, a pharmaceutically acceptable salt thereof, and uses of them as a therapeutic agent, specifically as a phosphoinositide 3-kinase ? (PI3K?) inhibitor, where the definitions of the substituents in formula (I) are identical to the definitions in the description.Type: ApplicationFiled: July 6, 2020Publication date: August 18, 2022Applicants: ZHEJIANG HISUN PHARMACEUTICAL CO., LTD., HISUN ACCURAY THERAPEUTICS CO., LTD.Inventors: Hejun LV, Yutao MA, Haibo QIU, Wenwen ZHAO, Taishan HU, Lei CHEN
-
Publication number: 20220227699Abstract: The present invention relates to aromatic ring or heteroaromatic ring derivatives, a preparation method therefor and applications thereof in medicine. Specifically, the present invention relates to aromatic ring or heteroaromatic ring derivatives represented by general formula (I), a preparation method therefor and pharmaceutically acceptable salts thereof, as well as a use thereof as therapeutic agents, especially uses as angiotensin II type 2 receptor (AT2R) antagonists, wherein the definition of each substituent in the general formula (I) is the same as the definition thereof in the description.Type: ApplicationFiled: April 1, 2020Publication date: July 21, 2022Applicants: ZHEJIANG HISUN PHARMACEUTICAL CO., LTD., HISUN ACCURAY THERAPEUTICS CO., LTD.Inventors: Yanghui GUO, Weiwei LIAO, Lichen MENG, Taishan HU, Lei CHEN, Guoping JIANG
-
Publication number: 20220220107Abstract: Crystal forms A, B, C, D, E, F, G and H of a compound represented by formula I and a preparation method therefor, as well as medical uses for the various crystal forms and advantages thereof in various aspects.Type: ApplicationFiled: May 21, 2020Publication date: July 14, 2022Applicant: ZHEJIANG HISUN PHARMACEUTICAL CO., LTD.Inventors: Jianfeng ZHENG, Liang ZHANG, Min ZHAO, Zhenjuan SHI, Xufei LI, Zhiqing YANG
-
Patent number: 11384097Abstract: Provided are a tetrahydroisoquinoline derivative, a preparation method therefor and an application thereof in medicine. In particular, provided are a tetrahydroisoquinoline derivative represented by general formula (I), a preparation method therefor and a pharmaceutically acceptable salt thereof as well as use thereof as a therapeutic agent, in particular as an angiotensin II type 2 receptor (AT2R) antagonist, wherein definitions of substituent groups in the general formula (I) are the same as definitions in the description.Type: GrantFiled: June 18, 2019Date of Patent: July 12, 2022Assignee: ZHEJIANG HISUN PHARMACEUTICAL CO., LTD.Inventors: Yanghui Guo, Xiangui Huang, Weiwei Liao, Lichen Meng, Taishan Hu, Lei Chen, Guoping Jiang
-
Patent number: 11371026Abstract: The present invention relates to a DoxA protein mutant having an amino acid sequence set forth in SEQ ID NO: 16, and coding gene thereof. The protein mutant or the coding gene thereof can be used for producing epirubicin. The present invention further relates to a Streptomyces capable of efficiently expressing epirubicin, which is constructed by replacing the dnmV gene of a starting Streptomyces in situ with the avrE gene and mutating the doxA gene of the starting Streptomyces into a gene encoding the protein set forth in SEQ ID NO: 16. The fermentation broth of this Streptomyces has an epirubicin potency of up to 102.0 ?g/ml.Type: GrantFiled: May 8, 2017Date of Patent: June 28, 2022Assignee: Zhejiang Hisun Pharmaceutical Co., Ltd.Inventors: Min Zhou, Xing Jiang, Shuang Han, Yingying He, Linghui Zheng
-
Publication number: 20220177450Abstract: The present invention relates to a piperazine amide derivative as represented by formula (I) or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition thereof, and use of same as a therapeutic agent, especially as a selective Rearranged During Transfection (RET) kinase inhibitor. Ring a, ring e, X1, X2, X3, X4, R1, R2, R3, R4, R4?, R5, R5?, R6, R6?, R7, R7?, R8, m and n have the same definitions as those in the specification.Type: ApplicationFiled: April 9, 2020Publication date: June 9, 2022Applicant: ZHEJIANG HISUN PHARMACEUTICAL CO., LTD.Inventors: Panpan ZHANG, Sunli YAN, Ying LI, Chenli GUO, Wenjian QIAN, Cheng YE, Zhengzheng SHI, Taishan HU, Lei CHEN
-
Patent number: 11142531Abstract: The present invention relates to a cyano-substituted heteroarylpyrimidinone derivative represented by formula (I), a preparation method therefor and a use thereof as a therapeutic agent, in particular a use as an acetyl-CoA carboxylase (ACC) inhibitor, and the definition of each substituent in formula (I) is the same as the definition in the description.Type: GrantFiled: March 23, 2018Date of Patent: October 12, 2021Assignee: ZHEJIANG HISUN PHARMACEUTICAL CO., LTD.Inventors: Hejun Lv, Dongliang Guan, Mingxiao Chen, Jinglu Wang, Lin Qian
-
Publication number: 20210277021Abstract: Provided are a tetrahydroisoquinoline derivative, a preparation method therefor and an application thereof in medicine. In particular, provided are a tetrahydroisoquinoline derivative represented by general formula (I), a preparation method therefor and a pharmaceutically acceptable salt thereof as well as use thereof as a therapeutic agent, in particular as an angiotensin II type 2 receptor (AT2R) antagonist, wherein definitions of substituent groups in the general formula (I) are the same as definitions in the description.Type: ApplicationFiled: June 18, 2019Publication date: September 9, 2021Applicant: ZHEJIANG HISUN PHARMACEUTICAL CO., LTD.Inventors: Yanghui GUO, Xiangui HUANG, Weiwei LIAO, Lichen MENG, Taishan HU, Lei CHEN, Guoping JIANG
-
Publication number: 20210221797Abstract: The present invention relates to a pyrimidine derivative, a method for preparing same and use thereof in medicine. In particular, the present invention relates to a pyrimidine derivative represented by general formula (I), a method for preparing same and a pharmaceutically acceptable salt thereof as well as use thereof as a therapeutic agent, in particular as a FGFR4 kinase inhibitor, definitions of each substituent in the general formula (I) being the same as those defined in the description.Type: ApplicationFiled: March 31, 2021Publication date: July 22, 2021Applicant: Zhejiang Hisun Pharmaceutical Co., Ltd.Inventors: Lei Chen, Dongliang Guan, Hua Bai, Jun Gou, Weifeng Zhao, Zhongli Wang, Long Ling, Yutao Ma
-
Publication number: 20210145754Abstract: An HS-25 tablet, an HS-25 solid dispersion composition, a preparation method therefor and usage thereof. The HS-25 tablet is made by using HS-25 and excipients for wet granulation, drying, granulating and tablet pressing.Type: ApplicationFiled: November 23, 2018Publication date: May 20, 2021Applicant: ZHEJIANG HISUN PHARMACEUTICAL CO., LTD.Inventors: Li DING, Jun DAI, Chunrong FENG, Changliang DAI
-
Patent number: 10844415Abstract: The invention provides a construction method of spinosad heterologous expression strain, a spinosad heterologous expression strain obtained by the method and use thereof in preparing spinosad. The method utilizes a plurality of homologous recombination to replace the erythromycin synthetic gene cluster of Saccharopolyspora erythraea with the spinosad synthetic gene cluster and the rhamnose synthetic gene cluster, such that the Saccharopolyspora erythraea produces spinosad.Type: GrantFiled: November 14, 2014Date of Patent: November 24, 2020Assignee: Zhejiang Hisun Pharmaceutical Co., LTD.Inventors: Jun Huang, Zhen Yu, Meihong Li, Linghui Zheng, Na Li, Haibin Wang, Hua Bai
-
Publication number: 20200207745Abstract: The present invention relates to a pyrimidine derivative, a method for preparing same and use thereof in medicine. In particular, the present invention relates to a pyrimidine derivative represented by general formula (I), a method for preparing same and a pharmaceutically acceptable salt thereof as well as use thereof as a therapeutic agent, in particular as a FGFR4 kinase inhibitor, definitions of each substituent in the general formula (I) being the same as those defined in the description.Type: ApplicationFiled: February 25, 2020Publication date: July 2, 2020Applicant: Zhejiang Hisun Pharmaceutical Co., Ltd.Inventors: Lei Chen, Dongliang Guan, Hua Bai, Jun Gou, Weifeng Zhao, Zhongli Wang, Long Ling, Yutao Ma